380 related articles for article (PubMed ID: 29692248)
1. A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
Cacciari B; Spalluto G; Federico S
Mini Rev Med Chem; 2018; 18(14):1168-1174. PubMed ID: 29692248
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biological evaluation and molecular modelling studies of 1,3,7,8-tetrasubstituted xanthines as potent and selective A
Rohilla S; Bansal R; Kachler S; Klotz KN
Bioorg Chem; 2019 Jun; 87():601-612. PubMed ID: 30933785
[TBL] [Abstract][Full Text] [Related]
3. Development of Adenosine A
Zheng J; Zhang X; Zhen X
ACS Chem Neurosci; 2019 Feb; 10(2):783-791. PubMed ID: 30199223
[TBL] [Abstract][Full Text] [Related]
4. Selected C8 two-chain linkers enhance the adenosine A
van der Walt MM; Terre'Blanche G
Eur J Med Chem; 2017 Jan; 125():652-656. PubMed ID: 27721150
[TBL] [Abstract][Full Text] [Related]
5. The adenosine A(2A) antagonistic properties of selected C8-substituted xanthines.
Van der Walt MM; Terre'Blanche G; Petzer A; Lourens AC; Petzer JP
Bioorg Chem; 2013 Aug; 49():49-58. PubMed ID: 23892098
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of the adenosine A
Sun B; Bachhawat P; Chu ML; Wood M; Ceska T; Sands ZA; Mercier J; Lebon F; Kobilka TS; Kobilka BK
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2066-2071. PubMed ID: 28167788
[TBL] [Abstract][Full Text] [Related]
7. 2-Benzylidene-1-Indanone Analogues as Dual Adenosine A1/A2a Receptor Antagonists for the Potential Treatment of Neurological Conditions.
van Rensburg HJ; Legoabe L; Terre'Blanche G; Van der Walt M
Drug Res (Stuttg); 2019 Jul; 69(7):382-391. PubMed ID: 30616250
[TBL] [Abstract][Full Text] [Related]
8. Do caffeine and more selective adenosine A
Chen JF; Schwarzschild MA
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
[TBL] [Abstract][Full Text] [Related]
9. Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.
Pinna A
CNS Drugs; 2014 May; 28(5):455-74. PubMed ID: 24687255
[TBL] [Abstract][Full Text] [Related]
10. A
Lambertucci C; Marucci G; Catarzi D; Colotta V; Francucci B; Spinaci A; Varano F; Volpini R
Curr Med Chem; 2022 Aug; 29(28):4780-4795. PubMed ID: 35184706
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine A
Harmse R; van der Walt MM; Petzer JP; Terre'Blanche G
Bioorg Med Chem Lett; 2016 Dec; 26(24):5951-5955. PubMed ID: 27836398
[TBL] [Abstract][Full Text] [Related]
12. Targeting the adenosine A
Zhao Y; Zhou YG; Chen JF
Chin J Traumatol; 2024 May; 27(3):125-133. PubMed ID: 37679245
[TBL] [Abstract][Full Text] [Related]
13. 5-Substituted 2-benzylidene-1-tetralone analogues as A
Janse van Rensburg HD; Terre'Blanche G; van der Walt MM; Legoabe LJ
Bioorg Chem; 2017 Oct; 74():251-259. PubMed ID: 28881253
[TBL] [Abstract][Full Text] [Related]
14. History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents.
Preti D; Baraldi PG; Moorman AR; Borea PA; Varani K
Med Res Rev; 2015 Jul; 35(4):790-848. PubMed ID: 25821194
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel 1,3,5-triazine as adenosine A
Masih A; Agnihotri AK; Srivastava JK; Pandey N; Bhat HR; Singh UP
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22659. PubMed ID: 33156955
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A(2A) Receptor Antagonists and Parkinson's Disease.
Shook BC; Jackson PF
ACS Chem Neurosci; 2011 Oct; 2(10):555-67. PubMed ID: 22860156
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling.
Khanfar MA; Al-Qtaishat S; Habash M; Taha MO
Chem Biol Interact; 2016 Jul; 254():93-101. PubMed ID: 27216633
[TBL] [Abstract][Full Text] [Related]
18. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
19. Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
Petzer JP; Petzer A
Curr Med Chem; 2015; 22(8):975-88. PubMed ID: 25544641
[TBL] [Abstract][Full Text] [Related]
20. Potent and selective adenosine A(2A) receptor antagonists: [1,2,4]-triazolo[4,3-c]pyrimidin-3-ones.
Harris JM; Neustadt BR; Zhang H; Lachowicz J; Cohen-Williams M; Varty G; Hao J; Stamford AW
Bioorg Med Chem Lett; 2011 Apr; 21(8):2497-501. PubMed ID: 21398125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
